Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Has Average Price Target of $22.43

Key Points

• Analysts broadly favor Arcturus Therapeutics: Eleven firms give the stock a consensus “Moderate Buy” rating, with an average 12-month price target of $22.43, though ratings range from sell to strong buy.
• Institutional ownership is high at 94.54%: Several investors recently increased or initiated positions, while the stock opened at $14.66—above its 50-day and 200-day moving averages but below its 52-week high of $24.17.
• The company remains unprofitable: Arcturus reported a quarterly loss of $0.84 per share, better than the expected $1.00 loss, but revenue of $2.96 million fell short of estimates and analysts expect a full-year loss of $3.48 per share.

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $22.43.

Several brokerages have commented on ARCT. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research note on Thursday, September 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. Roth Capital reissued a "buy" rating and issued a $41.00 price objective on shares of Arcturus Therapeutics in a research note on Wednesday, September 2nd. Citigroup upgraded shares of Arcturus Therapeutics from a "neutral" rating to a "buy" rating and raised their target price for the company from $8.00 to $20.00 in a research report on Thursday, September 24th. Finally, Wall Street Zen cut shares of Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ARCT. Versant Capital Management Inc raised its position in shares of Arcturus Therapeutics by 648.6% during the third quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 2,627 shares during the period. Hsbc Holdings PLC lifted its holdings in shares of Arcturus Therapeutics by 7.7% in the 2nd quarter. Hsbc Holdings PLC now owns 56,895 shares of the biotechnology company's stock worth $394,000 after purchasing an additional 4,070 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in Arcturus Therapeutics in the 2nd quarter valued at $80,000. ADAR1 Capital Management LLC acquired a new stake in Arcturus Therapeutics in the 1st quarter valued at $116,000. Finally, Diversify Wealth Management LLC bought a new stake in Arcturus Therapeutics during the 1st quarter valued at $133,000. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Price Performance

NASDAQ ARCT opened at $14.66 on Tuesday. The business has a fifty day moving average price of $12.17 and a two-hundred day moving average price of $9.13. Arcturus Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $24.17. The stock has a market capitalization of $416.64 million, a PE ratio of -4.43 and a beta of 2.48.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%.The company had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. As a group, sell-side analysts expect that Arcturus Therapeutics will post -3.48 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines.

The company's research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.